3378 — Hanx Biopharmaceuticals (Wuhan) Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$2.32bn
- HK$2.48bn
Annual cashflow statement for Hanx Biopharmaceuticals (Wuhan) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | -93.4 | -123 |
| Depreciation | ||
| Amortisation | ||
| Non-Cash Items | 47.4 | 26.2 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -7 | -13.8 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Other Operating Cash Flow | ||
| Cash from Operating Activities | -52 | -105 |
| Capital Expenditures | -4.78 | -6.21 |
| Purchase of Fixed Assets | ||
| Purchase / Acquisition of Intangibles | ||
| Other Investing Cash Flow Items | 98.7 | 103 |
| Sale of Business | ||
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Other Investing Cash Flow | ||
| Cash from Investing Activities | 94 | 96.6 |
| Financing Cash Flow Items | 0 | -2.55 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 90.2 | 6.49 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 132 | -0.786 |